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A 65-year-old Italian physician affected by Familial Mediterranean fever (FMF) was
hospitalized due to progressive abdominal enlargement, which had begun 6 months
before admission. Physical examination revealed ascites and bilateral leg edema.
Abdominal CT scan showed ascitic fluid and extensive multiple peritoneal implants;
peritoneal CT-guided biopsy revealed an epithelial-type malignant mesothelioma. The
patient’s past medical history revealed recurrent episodes of abdominal pain and fever
from the age of 2. Clinical diagnosis of FMF was suspected at the age of 25, while genetic
analysis, performed at the age of 50, confirmed homozygosity for the M694I mutation
in the MEFV gene. Treatment with the first line FMF drug colchicine was started and
stopped several times because of worsened leukopenia. The patient in fact had a history
of asymptomatic leukopenia/lymphopenia from an early age; the intake of colchicine
aggravated his pre-existing problem until the definitive suspension of the drug. As for
second-line drugs, canakinumab was first prescribed, but due to prescription issues, it
was not possible to be administered.When hewas given anakinra, there was a worsening
of leukopenia leading to septic fever. Systematic literature review indicates that, in most
cases, recurrent peritoneal inflammation results in benign peritoneal fibrosis or less
commonly in encapsulating peritonitis. There are only a few reported cases of recurrent
peritoneal inflammation progressing from FMF to peritoneal mesothelioma (MST). In such
cases, intolerance to colchicine or its erratic intake may lead to long-term recurrent
inflammation, which usually precedes the development of the tumor, while pre-existing
leukopenia, as in our patient, could also be a factor promoting or accelerating the tumor
progression. In conclusion, we suggest that in the presence of intolerance or resistance
to colchicine, interleukin (IL)-1 inhibition could suppress peritoneal inflammation and
prevent MSTs.
Keywords: Familial Mediterranean fever (FMF), malignant mesothelioma (MST), colchicine, peritoneal recurrent
inflammation, canakinumab, anakinra, interleukin (IL)-1b inhibition
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INTRODUCTION
Familial Mediterranean fever (FMF) is an autoinflammatory
hereditary disorder characterized by recurrent bouts of fever and
serosal inflammation at one or multiple sites (1). It is inherited as
a single autosomal recessive trait (2), and common complications
include secondary (AA) amyloidosis and peritoneal adhesions.
The goals of FMF treatment are the prevention of acute
attacks and the reduction of subclinical inflammation between
attacks. The disease and its complications are usually managed
with colchicine, which is the standard recommendation in all
patients with FMF (3). Approximately 5–10% of FMF patients
are colchicine resistant, and 2–5% do not tolerate the drug due to
its side effects (4). The currently preferred second-line treatment
for these patients is by represented interleukin (IL)-1 inhibitors
(canakinumab or anakinra) (5–8).
This case report describes the history of an FMF patient
who was intolerant to colchicine, developed MST, and in whom
treatment with IL-1 inhibitors was unfortunately delayed.
We hereby discuss the association between Familial
Mediterranean fever and the appearance of malignant
mesothelioma; very few cases have been described in the
literature. Although such association is controversial (9, 10),
this and other similar cases lead us to support the relationship
of chronic peritoneal inflammation and the development of
MST. Colchicine resistance or intolerance promotes chronic
inflammation; therefore, IL-1 biological inhibitors, by acting
on the inflammatory cascade and its mediators, may prevent
amyloidosis as well as recurrent peritoneal inflammation in
these patients.
CASE REPORT
In January 2019, a 65-year-old physician affected by Familial
Mediterranean fever was hospitalized at our Center for
progressive abdominal enlargement, which had begun 6 months
before admission. Physical examination revealed ascites and
bilateral leg edema.
Past medical history dates back to the age of 2 with self-
limited acute abdominal pain bouts associated with fever. The
patient was completely asymptomatic between attacks. These
episodes lasted from 24 to 72 h and occurred at unpredictable
periods ranging from a weekly interval to twice a year. They
were also accompanied by an erysipelas-like erythema and
sometimes orchitis.
After becoming a doctor, the patient diagnosed himself with
Familial Mediterranean fever (FMF) at the age of 25. In 2003,
at the age of 50 the genetic test was performed in our Center
and revealed M694I homozygous mutations of the exon 10 of the
MEFV gene (mutation c.2082G>A).
The patient had a long history of stable mild
leukopenia/lymphopenia since at an early age in the absence of
any recurrent infections, without familial history.
Blood exams (white cell count and lymphocyte typing)
confirmed this data: WBC 3,680/mm3, lymphocytes 1,170/mm3.
The subtype analysis showed marked reduction in CD3+ T
lymphocytes with normal ratio CD4/CD8; CD3+ was 853 mm3
(72.4%), CD4+was 542mm3 (46%), CD8+was 271mm3 (23 %),
CD4/CD8 ratio was 2, CD19+ was 47 mm3 (4%), and CD16+
was 2% of the total lymphocytes.
Serology for HIV, EBV, and CMV was negative.
Autoantibodies such as ANA, anti-DNA, anti-endomysial,
and anti G.P.C. antibodies were absent, and immunoglobulin
levels were normal. Mantoux test was repeatedly negative,
confirmed by Quantiferon test. Gastroscopy showed chronic
gastritis with focal atrophy, H.P. negative; Vitamin B12 and folic
acid levels were normal.
In addition, as it is usual in FMF patients with a delayed
diagnosis, he had had appendectomy at age 20. Interestingly,
during a laparoscopic hernioplasty performed at the age of 45, a
peritoneal biopsy revealed “Mononuclear cellular infiltrates with
fibrotic appearance.”
He had always worked in the Emergency Room; no asbestos
exposure was evident in his past medical history. After FMF
diagnosis was established, multiple trials of 1 mg/day of
colchicine treatment were performed, but given the side effect of
worsening neutropenia (<1,500 mm3) and the consequent risk
of infections, it was stopped. As an E.R. physician being exposed
to sick contacts, he decided to treat himself with paracetamol or
NSAIDs à la demande during the attacks.
Since August 2018, the fever had become persistent with
monthly recrudescence, and in October 2018, the patient
was admitted to another hospital due to atrial fibrillation,
ascites, and bilateral leg edema. Peritoneal percutaneous
drainage was performed, and fluid cytology analysis revealed
“hyperplastic-dysplastic cellular figures, suggesting uncertain
mesothelial proliferation: reactive or neoplastic.” The patient
refused the CT-guided biopsy.
To control the fever, canakinumab, a specific IL-1β
(interleukin 1-beta) monoclonal antibody was prescribed in
2018. Owing to regulatory prescription limitations in the
region where the patient resided, it was decided that anakinra,
an interleukin-1 receptor antagonist (IL-1RA), would be the
treatment of choice. When he was given anakinra, there was a
worsening of leukopenia leading to septic fever.
In January 2019, he was admitted to our hospital (Periodic
Fever Research Centre) to investigate the etiology of fever
and to exclude a neoplastic origin of ascites. Blood cultures
were performed and revealed the presence of Staphylococcus
aureus MRSA, which was treated with Vancomycin. Abdominal
CT scan showed multiple extensive peritoneal lesions, and
peritoneal fluid cytology analysis confirmed the presence
of neoplastic cells. CT-guided biopsy was performed and
a histological diagnosis of epithelioid MST (Figures 1, 2)
(phenotype: CK-AE1AE3+, CK5/6+, Calretinin+, Vimentin+,
WT1+, BerEp4–) was established. Despite the initial plan of
tumor surgical resection plus intraabdominal chemotherapy
(HYPEC), the clinical picture deteriorated rapidly with
worsening of the general conditions and death after
2 weeks.
DISCUSSION
Monogenic periodic fever syndromes are rare conditions, which
have made possible the discovery of the inflammasome-related
pathologies (11) and the effects of recurrent inflammation.
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In this setting, FMF is defined as an hereditary
autoinflammatory disorder typically encountered in certain
Mediterranean populations, such as Jewish, Middle-east,
Anatolian Turk and Armenian, Greek, and Italian (12–14).
FIGURE 1 | Proliferation of large atypical cells with abundant eosinophilic
cytoplasm organized in nests and ribbons (hematoxylin–eosin).
FMF is characterized by recurrent attacks of fever and serosal
inflammation. The mutant FMF gene (MEFV gene) is located on
the short arm of chromosome 16 and is known to have pleiotropic
effects (15).
The MEFV gene codifies for a protein known as
Pyrin/Marenostrin, whose mutation has been associated
with a gain-of-function (16) that enhances inflammation in
response to trigger factors (PAMPs/DAMPs etc.).
An association of MEFV mutations with some neoplasms (as
multiple myeloma) has been reported in the literature [it has
been speculated that MEFV can act as an onco-suppressor gene
(17)], but is not confirmed. FMF usually presents as recurrent
or, less commonly, sporadic fever attacks associated with serosal
inflammation involving the peritoneum, pleura, or synovia.
Sometimes the onset is as an acute abdomen, and recurrent
laparotomies are unable to identify the underlying pathology.
Acute attacks are typically accompanied by elevation of
inflammatory markers such asWBC, CRP, and SAA. FMF should
be suspected in all individuals with recurrent febrile episodes
associated with peritonitis, synovitis or pleurisy, recurrent
erysipelas-like erythema, in an individual with compatible
family history or specific ethnic origin (18). Genetic testing is
useful to support diagnosis and exclude other autoinflammatory
syndromes mimicking FMF. AA amyloidosis (19) is a well-
known complication in patients with long-standing FMF before
colchicine treatment era. Other long-term complications include
FIGURE 2 | Legend: (A) Keratin AE1AE3. (B) Vimentin. (C) Calretinin. (D) WT1.
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peritoneal adhesions due to recurrent peritonitis, leading to small
bowel obstruction, infertility, peritoneal fibrosis, encapsulating
peritonitis, but rarely, peritoneal MST has been reported (9, 10).
Malignant MST is a rare highly lethal malignancy originating
from the lining of pleural, peritoneal, pericardial, or tunica
vaginalis serous membranes. One-third of the MSTs are
peritoneal in origin, and the most important cause of these
tumors is represented by asbestos exposure, whereby incidence
rates range from 13 to 100% among exposed population
goals (20).
Besides leading to fibrosis and encapsulating peritonitis, the
long-standing peritoneal inflammation typical of FMF patients
could predispose to MST development as evidenced by this
and other case reports described in the literature. Up to this
date, several examples of chronic or recurrent inflammatory
conditions linked to cancer have been well-established, for
instance Barrett’s metaplasia with esophageal cancer and
HCV infection with hepatocellular carcinoma, among others.
Although the exact mechanism by which inflammation leads to
cancer development is not well-known, in chronic inflammatory
conditions, a combination of DNA repair abnormalities and
inappropriate immune response may lead to, and promote,
oncogenesis (21).
In this setting, the cell proliferation of repairing tissue
damage, with release of substances, promote cell survival, tissue
remodeling, and angiogenesis. Mediators produced by activated
immune cells may lead to oxidative stress resulting in genomic
instability and mutations, promoting further genotoxicity (22).
Such mutations arising in chronic inflammation may give origin
to malignant proliferations.
In our report, there was neither a history of exposure to
asbestos nor first-degree relatives with neoplasms, lymphomas, or
MST. Moreover, 20 years before the development of MST in our
patient, the histology of peritoneal biopsy documented benign
cell infiltrations with fibrotic appearance.
With regard to leuko-lymphopenia, lymphocytic typing
showed a marked reduction in CD8+ T– and CD16+
lymphocytes (NK cells). In the absence of ongoing infections,
a suggestive medical history of primitive immunodeficiency,
leukopenia was considered a benign idiopathic form (23).
Therefore, long-standing recurrent peritoneal inflammation
may have played an important role in the pathogenesis of
MST, while leukopenia/lymphopenia may have reduced immune
surveillance against activated/proliferative mesothelial cells after
the onset of DNA mutagenesis.
Since the clinical history of this case raises suspicion
of an association between recurrent uncontrolled peritoneal
inflammation and increased risk of MST, we searched all FMF
cases associated with MST, reported in the literature (Table 1).
We collected nine cases of peritoneal malignant mesothelioma
and two cases of peritoneal benign cystic mesothelioma cases,
from which several conclusions can be drawn (10, 24–31):
1. None of the above-mentioned MST patients with FMF had a
history of asbestos exposure.
2. Almost all FMF case reports have peritoneal MSTs (except
for one case of pleural mesothelioma in a patient with FMF
and rheumatoid arthritis), in spite most malignant MSTs
affect the pleural membrane in the general population. Such
finding can be explained by the fact that in more than
70% of FMF patients, chronic inflammation is localized at
the level of the peritoneum, whereas the pleura is involved
in only 30% of cases (20, 32, 33), thus reinforcing the
hypothesis that local chronic inflammation may have a role in
the pathogenesis.
3. Many of these MST cases reported (10, 26, 27, 30) a poor
compliance in the intake of colchicine related to its side effects.
TABLE 1 | FMF cases associated with MST.
References Age of patient Type of mesothelioma Asbestos
exposure
Survival Use of colchicine
Eryilmaz et al. (24) 43-year-old man Peritoneal benign cystic
mesothelioma (BCM)
No Survival Regular
Challita et al. (25) 50-year-old woman Malignant pleural
mesothelioma
No Not clear Regular
Sahin et al. (26) 51-year-old man Malignant peritoneal
mesothelioma
No 1 month Not constant
Hershcovici et al. (27) Patient 1: 61-year-old man
Patient 2: 38-year-old woman
Malignant peritoneal
mesothelioma
No Not mentioned Patient 1: regular;
Patient 2: not constant
Bani-Hani and Gharaibeh (28) 49-year-old man Malignant peritoneal
mesothelioma
No 13 months Not clear
Curgunlu et al. (29) 25-year-old woman Peritoneal benign cystic
mesothelioma (BCM)
Unknown Survival Regular
Belange et al. (30) 60-year-old man Malignant peritoneal
mesothelioma
No 2 months Not constant
Gentiloni et al. (10) 39-year-old man Malignant peritoneal
mesothelioma
No 6 months Not constant
Chahinian et al. (31) Man, age not mentioned Malignant peritoneal
mesothelioma
Not Not mentioned Regular
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These cases belong to a period when biological IL-1 inhibitors
were not yet available in the drug market.
4. The report of Gentiloni et al. (10) showed a peritoneal MST
in one of two FMF brothers; the first one not treated with
colchicine developed MST, after 25 years of diagnostic delay.
The second one, treated by colchicine without diagnostic
delay, never developed MST.
5. Two patients were affected by peritoneal benign cystic
mesothelioma (BCM) (24, 29), which is usually considered
an entirely different entity with a much better prognosis
and onset at a younger age. However, BCM and MST
are two conditions histologically different with a distinct
course, although having common inflammatory recurrent
triggers and perhaps different predisposing factors. Moreover,
a long-term follow-up of these BCM patients has not
been described.
6. The mean age of onset in malignant MST (50 years)
appears to be higher than those of the two patients with
BCM (34 years), but this should be related to the duration
and severity of FMF and the type of genetic mutation
(exon 10 mutations are associated with a more severe
disease course).
CONCLUSIONS
We describe a case of peritoneal MST developing in an
FMF patient who could not be treated with colchicine. This
is the second case of MST in our Center, where 450 FMF
patients (mainly from the South and Center of Italy) have
been in follow-up since 1997; both patients were not treated
with colchicine.
Approximately 5–10% of FMF patients are colchicine non-
responders, and 2–5% do not tolerate the drug mainly due to
its side effects (4). Consequently, some patients do not take
the drug at the prescribed dosage, resulting in poor control
of inflammation.
In the clinical practice, the goals of FMF treatment
are prevention of acute attacks and suppression of any
subclinical inflammation between attacks to reduce the risk
of complications. The first-line treatment is represented by
colchicine, which is recommended in all FMF patients, regardless
of the frequency and intensity of attacks. Intermittent use of high-
dose colchicine or only during acute attacks is not recommended
since it does not protect from complications associated to low-
grade inflammation occurring during asymptomatic intervals
(3, 34, 35).
Colchicine affects neutrophilic migration in response to
inflammatory stimuli, while blocking mitotic activity occurs
at higher dosages than those used in FMF (36); however, no
cytostatic effect of colchicine is expected at the common dosage,
being a reversible microtubule depolymerizer.
In recent years, the IL-1 inhibitor biologic drugs became
available (canakinumab, anakinra, and rilonacept) for treatment
of FMF patients with colchicine resistance or intolerance.
The choice of IL-1 inhibitor is based on a combination of
factors including regulatory or insurance requirements, route of
administration, and cost. Canakinumab is generally preferred
due to patient’s compliance, since it is administered as a
subcutaneous injection every 4–8 weeks.
Analysis of the association of FMF and MST described in
the literature shows that many of these FMF patients are not
compliant with colchicine treatment.
Therefore, in case of colchicine intolerance (as resistance),
IL-1 inhibiting biological drugs, acting on the inflammatory
cascade and its mediators, could prevent amyloidosis as long-
standing recurrent peritoneal inflammation in FMF patients. It
is logical to ask what the patient’s prognosis would have been if
he could have received regular treatment with colchicine or if IL-
1 inhibitors had been administered timely many years before the
MST diagnosis.
The patient’s last wish was for his medical history to be
described in detail.
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